Protective monoclonal antibody targeting mycobacterium tuberculosis OmpA as well as preparation method and application of protective monoclonal antibody

By developing monoclonal antibodies targeting M. tuberculosis OmpA, the problem of limited effectiveness of existing vaccines in preventing adults and meningitis tuberculosis has been solved, and effective identification and neutralization of M. tuberculosis has been achieved, especially in tolerance and resistance The drug strain has significant effects in front of it and provides an alternative antibiotic treatment plan.

CN118930645AActive Publication Date: 2024-11-12CHINA AGRI UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411095825.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-11-12
Estimated Expiration
2044-08-09

AI Technical Summary

Technical Problem

The existing tuberculosis vaccines have limited effectiveness in preventing adults and meningitis tuberculosis, and anti-tuberculosis drug-resistant strains are becoming increasingly serious. Traditional vaccines mainly rely on T-cell-mediated cellular immunity, and lack effective humoral immune-mediated anti-tuberculosis strategies. .

Method used

Develop protective monoclonal antibodies targeting M. tuberculosis OmpA and their preparation methods. The antibodies are expressed and purified by recombinant technology to recognize and neutralize M. tuberculosis, and provide an antigen-binding fragment or polypeptide targeting OmpA protein. , used to immunize animals and generate specific antibodies for the prevention or treatment of tuberculosis.

Benefits of technology

The specific identification and neutralization of Mycobacterium tuberculosis has been achieved, which significantly reduces the risk of infection in tuberculosis, especially with broad-spectrum effects when facing drug-resistant strains, providing a treatment plan that replaces traditional antibiotics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930645A_ABST
    Figure CN118930645A_ABST
Patent Text Reader

Abstract

The invention provides a protective monoclonal antibody targeting mycobacterium tuberculosis OmpA as well as a preparation method and application of the protective monoclonal antibody. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, HCDR1-3 sequences of the heavy chain variable region are shown as SEQ ID NO: 1, 2 and 3, and LCDR1-3 sequences of the light chain variable region are shown as SEQ ID NO: 4, 5 and 6. The antibody provided by the invention can be used for treatment of tuberculosis, especially treatment of drug-resistant tuberculosis, and also can be used for prevention of tuberculosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a protective monoclonal antibody targeting Mycobacterium tuberculosis OmpA, a preparation method and an application thereof. Background Art

[0002] Tuberculosis is a chronic infectious disease transmitted through the respiratory tract, causing millions of deaths each year. Currently, the only commercial tuberculosis vaccine approved for use is Bacillus Calmette-Guérin (BCG), which is effective in preventing tuberculosis infection in infants and young children. However, the limitations of BCG in preventing tuberculosis infection in adults and the onset of meningitis tuberculosis have led to an urgent need to develop new anti-tuberculosis vaccines. Traditionally, as an intracellular parasite, its vaccine research and development has mainly focused on T cell-mediated cellular immunity, such as MVA85A. However, recent studies have prompted researchers to re-evaluate the importance of humoral immune mediation for anti-tuberculosis vaccine design. Reports in recent years have shown that antibodies that recognize tuberculosis surface antigens can play an immune protective role against tuberculosis. There are a large number of proteins and polysaccharides distributed on the surface of Mycobacterium tuberculosis, and it has been revealed that antibodies against a few surface proteins and polysaccharides can play an anti-tuberculosis function. However, according to bioinformatics prediction, there are 144 surface proteins distributed on the surface of Mycobacterium tuberculosis. The role of antibodies induced by these surface proteins in the anti-tuberculosis process is still not very clear. Establishing and characterizing the role of antibodies produced by these antigens in the anti-tuberculosis process will greatly promote the design of anti-tuberculosis vaccines.

[0003] The abuse of antibiotics has led to the emergence of drug-resistant Mycobacterium tuberculosis, especially the emergence of multidrug-resistant Mycobacterium tuberculosis, which poses a major challenge to global public health. With the development of monoclonal antibody preparation technology, its application in the field of pathogenesis has become more extensive, such as immunotherapy, diagnosis and cancer treatment. Thanks to the fact that antibodies are not easy to cause bacterial tolerance and produce toxicity similar to small molecule chemical drugs, antibody therapy has shown a very promising application space as an alternative to antibiotics. For complex bacterial typing, antibodies that recognize conserved antigens can show more efficient treatment. An antibody against the Salmonella type III secretion system antigen SipD can induce a broad-spectrum anti-Salmonella serotype effect, which provides an important inspiration for the development of broad-spectrum therapeutic antibodies against different subspecies. The OmpA protein encoded by the Mycobacterium tuberculosis gene Rv0899 is located on the surface of Mycobacterium tuberculosis and has a high homology among the known different Mycobacterium tuberculosis subspecies. Therefore, the establishment and characterization of OmpA-induced antibodies is of great significance for anti-tuberculosis treatment. Summary of the invention

[0004] The present invention aims to solve one of the technical problems in the related art at least to a certain extent. The present invention provides a protective monoclonal antibody specifically targeting the OmpA antigen of Mycobacterium tuberculosis and a preparation method thereof, and the monoclonal antibody can play an anti-tuberculosis role.

[0005] Specifically, the present invention provides the following technical solutions:

[0006] In a first aspect of the present invention, there is provided a protective monoclonal antibody or an antigen-binding fragment thereof targeting Mycobacterium tuberculosis OmpA, comprising a heavy chain variable region and a light chain variable region;

[0007] The HCDR1-3 sequences of the heavy chain variable region are shown in SEQ ID NO: 1, 2 and 3, respectively, or are sequences having an amino acid substitution, deletion or addition with respect to the sequence shown in SEQ ID NO: 1, 2 or 3;

[0008] The sequences of LCDR1 to 3 of the light chain variable region are shown in SEQ ID NOs: 4, 5 and 6, respectively, or are sequences having an amino acid substitution, deletion or addition with respect to the sequence shown in SEQ ID NOs: 4, 5 or 6;

[0009] The sequences shown in the HCDR1-3 and the sequences shown in the LCDR1-3 are obtained based on the IMGT definition scheme.

[0010] According to an embodiment of the present invention, the monoclonal antibody or antigen-binding fragment thereof has:

[0011] (a) the heavy chain variable region set forth in SEQ ID NO:7, or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology to the heavy chain variable region sequence set forth in SEQ ID NO:7; and

[0012] (b) a light chain variable region as set forth in SEQ ID NO:8, or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology to the light chain variable region sequence as set forth in SEQ ID NO:8.

[0013] According to an embodiment of the present invention, the monoclonal antibody or antigen-binding fragment thereof has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:8.

[0014] In a second aspect, the present invention provides an isolated polynucleotide encoding the monoclonal antibody or antigen-binding fragment thereof according to the first aspect.

[0015] According to an embodiment of the present invention, the polynucleotide includes a sequence encoding a heavy chain variable region as shown in SEQ ID NO:9 and a sequence encoding a light chain variable region as shown in SEQ ID NO:10.

[0016] The third aspect of the present invention provides a construct, which contains the isolated polynucleotide described in the second aspect.

[0017] In the fourth aspect of the present invention, a host cell is provided, wherein the host cell contains the isolated polynucleotide according to the second aspect or the construct according to the third aspect.

[0018] In a fifth aspect of the present invention, there is provided a method for producing a monoclonal antibody or an antigen-binding fragment thereof, comprising:

[0019] Cultivating a host cell, wherein the host cell is the host cell described in the fourth aspect, and

[0020] The monoclonal antibody or antigen-binding fragment thereof is collected from the culture.

[0021] In a sixth aspect of the present invention, a pharmaceutical composition is provided, comprising:

[0022] The monoclonal antibody or antigen-binding fragment thereof according to any embodiment of the first aspect; and

[0023] A pharmaceutically acceptable carrier.

[0024] In a seventh aspect, the present invention provides a kit, comprising: the monoclonal antibody or antigen-binding fragment thereof as described in any embodiment of the first aspect.

[0025] In an eighth aspect, the present invention provides use of the monoclonal antibody or antigen-binding fragment thereof described in the first aspect in preparing a reagent for detecting Mycobacterium tuberculosis OmpA, or in preparing a drug for preventing or treating a disease.

[0026] According to an embodiment of the present invention, the disease is tuberculosis caused by Mycobacterium tuberculosis.

[0027] According to an embodiment of the present invention, the drug is a preventive vaccine or a therapeutic drug.

[0028] In the ninth aspect of the present invention, an antigen protein or polypeptide is provided, wherein the antigen protein or polypeptide has the sequence shown in SEQ ID NO: 11. The provided antigen protein or polypeptide can be used to immunize animals, thereby being used to treat monoclonal antibodies or antigen-binding fragments that specifically target Mycobacterium tuberculosis OmpA, thereby being used to treat or prevent tuberculosis or drug-resistant tuberculosis. The provided antigen protein or polypeptide is a protein or polypeptide obtained by truncating the 50 amino acids (located in the transmembrane region) at the N-terminus of the OmpA protein.

[0029] According to a specific embodiment, the antigenic protein or polypeptide is encoded by the nucleic acid sequence shown in SEQ ID NO:12. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 It is a flow chart of antibody preparation and function identification provided according to an embodiment of the present invention.

[0031] Figure 2 The preparation of the OmpA antigen and its antibody according to Example 1 of the present invention. A is the result of agarose gel electrophoresis of the amplified OmpA gene; B is the result of SDS-PAGE identification of the OmpA protein; C is the result of Western-blot identification of the OmpA protein; D is the result of serum titer of mice after immunization with the antigen OmpA; E is the result of SDS-PAGE after purification and identification of antibody 1E1. F is the result of subtype identification of antibody 1E1; G is the result of antibody 1E1's recognition of BCG and whole Mycobacterium bovis.

[0032] Figure 3 The antibody function identification results provided in Example 2 of the present invention are shown in Figure 1. A is the result of flow cytometry analysis of antibody 1E1 affecting macrophage phagocytosis; B is the result of statistical flow cytometry analysis of macrophage phagocytosis; C is the result of fluorescence confocal analysis of phagolysosome formation; D is the percentage of phagolysosome formation by statistical confocal analysis; E is the result of antibody inhibiting BCG growth in mouse whole blood; F is the result of antibody 1E1 reducing bacterial load in mouse lungs.

[0033] Figure 4 This is the result of antibody homology modeling provided according to Example 3 of the present invention.

[0034] Figure 5 This is the result of predicting the structure of the antigen OmpA using Alphafold3 according to Example 3 of the present invention. DETAILED DESCRIPTION

[0035] The embodiments of the present invention are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, but should not be construed as limiting the present invention. In order to facilitate the understanding of those skilled in the art, some terms in the text are explained and illustrated. It should be noted that these explanations and illustrations are only used to facilitate understanding and should not be regarded as limiting the scope of protection of the present invention.

[0036] Herein, the term "antibody" is used in the broadest sense, referring to a protein or polypeptide comprising an antigen binding site or antigen binding fragment or antigen binding portion, covering natural antibodies and artificial antibodies of various structures, including but not limited to complete antibody forms or antigen binding fragments of antibodies. According to a specific embodiment, the antibody provided is a monoclonal antibody.

[0037] The monoclonal antibody or its antigen-binding fragment mentioned herein is usually separable or recombinant. "Separable" refers to being able to identify and separate and / or recycle from cells or cell cultures expressing polypeptides or proteins. Usually, separated polypeptides (e.g., separated antibodies) can be prepared by at least one purification step. "Separated antibodies" refer to other antibodies or antigen-binding fragments that are substantially free of different antigen-specifics (such as separated antibodies that specifically bind to Mycobacterium tuberculosis OmpA antigens that are substantially free of antibodies that specifically bind to antigens other than the OmpA antigen). "Recombinant" means that antibodies can be produced in exogenous host cells using genetic recombination techniques.

[0038] Herein, "comprising" or "including" means including the mentioned elements or steps, but does not exclude other elements or steps. Of course, unless otherwise stated, comprising or including also covers the situation consisting of the mentioned elements or steps. For example, when referring to comprising a specific sequence, it is also intended to cover antibodies consisting of the specific sequence.

[0039] The "affinity" or "binding affinity" mentioned herein is understood according to the common meaning in the art, and is used to reflect the strength and / or stability of the binding sites between an antigen and an antibody or an antigen-binding fragment.

[0040] "Specific binding" or "specifically binds to" a specific antigen or epitope, or "specific for" a specific antigen or epitope means distinguishing from non-specific interactions, and such specific binding can be measured by some methods commonly used in the art. The ability of an antibody or antigen to bind can be measured by enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art.

[0041] The names of amino acids used herein are represented by standard single-letter or three-letter codes commonly used in the art. The "homology" of sequences mentioned herein refers to the degree of sequence identity when comparing proteins, polypeptides or nucleic acid sequences. In order to determine homology, it can be achieved in a variety of ways known in the art. For example, publicly available software such as BLAST, ALIGN, BLAST-2 and other software can be used to obtain it. The amino acid substitutions mentioned herein can be conservative amino acid substitutions. "Conservative amino acid substitutions" of sequences mentioned herein refer to the replacement of another amino acid residue with a different amino acid residue having a side chain with similar physiological and chemical properties. For example, conservative amino acid substitutions may occur between amino acid residues with hydrophobic side chains (e.g., Met, Ala, Val, Leu, and Ile), between residues with neutral hydrophilic side chains (e.g., Cys, Ser, Thr, Asn, and Gln), between residues with acidic side chains (e.g., Asp, Glu), between amino acids with basic side chains (e.g., His, Lys, and Arg), or between residues with aromatic side chains (e.g., Trp, Tyr, and Phe). As is known in the art, conservative amino acid substitutions generally do not cause significant changes in the conformational structure of the protein, and thus the biological activity of the protein can be retained.

[0042] The CDR sequences of the antibodies shown herein are obtained in combination with existing database definition schemes, for example, in combination with the IMGT database (Ehrenmann F., Kaas Q. and Lefranc M.-P. Nucleic Acids Res., 38: D301-D307 (2010); Ehrenmann, F., Lefranc, M.-P. Cold Spring Harbor Protoc., 6: 737-749 (2011)). Of course, they can also be obtained by Kabat (for example, see USDept. of Health and Human Servies, "Sequences of Proteins of Immunological Interest" (1983)), Chothia (for example, see J. Mol. Biol. 196: 901-917 (1987)), etc. It is known to those skilled in the art that the differences in CDR sequences caused by differences in database definition schemes are also included in the protection scope of the present invention.

[0043] The monoclonal antibody provided can also be a humanized antibody. "Humanized antibody" refers to a molecule based on an antigen binding site derived from a non-human species, and an antibody based on the partial structure and sequence of a human immunoglobulin molecule. Compared to non-humanized antibodies, humanized antibodies retain the binding activity with the antigen and reduce the immunogenicity. The immunogenicity of humanized antibodies is lower, while retaining the binding activity of the antibody with the OmpA antigen. In at least some embodiments, the humanized antibody provided retains the CDR region amino acid sequence, and the FR framework region is replaced with a humanized framework region sequence. This replacement of the framework region sequence can be a partial replacement or a complete replacement. According to a specific embodiment, the partially humanized framework region sequence mentioned can be replaced by a framework region sequence after the humanized framework region sequence is replaced, and the key amino acids that affect the antibody structure and function are reversed. Humanized antibodies can be obtained by methods commonly used in the art (such as complementary determining region transplantation). Humanized framework region sequences can be obtained by published humanized sequences. For example, through database comparison and computer homology modeling, we can find the human FR region template with the greatest homology, comprehensively consider and determine the key residues that need to be reverse mutated in the FR region, and obtain high-affinity humanized antibodies. These sequences are usually recorded in commonly used databases, such as the PDB protein structure database, IMGT, Genebank and other databases. Humanized antibodies can be further reverse mutated to retain some properties of the original sequence, such as affinity and physiological activity.

[0044] The monoclonal antibody or antigen-binding fragment thereof mentioned herein is substantially pure. The term substantially pure means that the purity of the produced monoclonal antibody or antigen-binding fragment thereof can reach 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, etc.

[0045] The present invention provides a monoclonal antibody or an antigen-binding fragment thereof targeting Mycobacterium tuberculosis OmpA, comprising a heavy chain variable region and a light chain variable region;

[0046] The HCDR1-3 sequences of the heavy chain variable region are shown in SEQ ID NOs: 1, 2 and 3, respectively, or are sequences having an amino acid substitution, deletion or addition with respect to the sequence shown in SEQ ID NOs: 1, 2 or 3;

[0047] The sequences of LCDR1 to 3 of the light chain variable region are shown in SEQ ID NOs: 4, 5 and 6, respectively, or are sequences having an amino acid substitution, deletion or addition with respect to the sequence shown in SEQ ID NOs: 4, 5 or 6;

[0048] The sequences shown in the HCDR1-3 and the sequences shown in the LCDR1-3 are obtained based on the IMGT definition scheme.

[0049] According to a specific embodiment, the monoclonal antibody or antigen-binding fragment thereof has:

[0050] (a) the heavy chain variable region of SEQ ID NO:7, or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence homology to the heavy chain variable region of SEQ ID NO:7; and

[0051] (b) the light chain variable region shown in SEQ ID NO:8, or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence homology to the light chain variable region sequence shown in SEQ ID NO:8.

[0052] According to a specific embodiment, the monoclonal antibody or antigen-binding fragment thereof has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:8.

[0053] The provided monoclonal antibody or antigen-binding fragment thereof may further include an Fc region, and the Fc region may be humanized or non-humanized.

[0054]

[0055]

[0056] Isolated polynucleotides

[0057] The present invention also provides an isolated polynucleotide encoding the monoclonal antibody or antigen-binding fragment thereof. The isolated polynucleotide may be DNA, RNA, or cDNA, etc. The polynucleotide sequence encoding the monoclonal antibody may be obtained according to conventional methods of those skilled in the art. According to a specific embodiment, the nucleotide sequence encoding the heavy chain variable region is shown in SEQ ID NO: 9, and the nucleotide sequence encoding the light chain variable region is shown in SEQ ID NO: 10.

[0058] Constructs

[0059] The present invention also provides a construct, which includes the isolated polynucleotide mentioned herein. The construct can be obtained by methods commonly used in the art, such as by in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. For example, the polynucleotide can be inserted into the multiple cloning site of the expression vector to form a construct. The construct can contain a variety of operating factors such as promoters, terminators, marker genes, etc. as needed, and these operating factors can be operably connected to the polynucleotide. The promoter is usually used to provide a signal to start transcription. The promoter can select lactose promoter (Lac), Trp promoter, Tac promoter, PL and PR promoters of bacteriophage as needed; the terminator provides a signal for transcription termination during the transcription process, and the marker gene on the construct is often used for screening. Of course, there can also be enhancers as needed to enhance protein expression. The expression vector is not particularly limited, and can be some commercially available expression vectors, or it can be an expression vector artificially modified as needed, such as a plasmid, a bacteriophage, a virus, etc. The virus can be a plant cell virus, a mammalian cell virus, etc. The construct can express antibodies or proteins in vitro, and can also be transferred into cells to express antibodies or proteins.

[0060] Host cells

[0061] The present invention also provides a host cell, which contains the above-mentioned isolated polynucleotide or the above-mentioned construct. Any cell suitable for expressing antibodies or proteins with polynucleotides or constructs can be used as a host cell. The host cell can be a prokaryotic cell, such as a bacterial cell; it can also be a eukaryotic cell, such as a yeast cell, a mammalian cell, etc. Commonly used host cells can be yeast cells, CHO, HEK-293, COS cells, Drosophila S2 or Sf9 insect cells. Host cells containing polynucleotides or constructs can be obtained by using methods commonly used in the art, such as microinjection, electroporation, chemical transfection, virus-mediated transformation, etc.

[0062] Method for producing monoclonal antibodies or antigen-binding fragments thereof

[0063] The present invention further provides a method for producing a monoclonal antibody or an antigen-binding fragment thereof, comprising: culturing the host cell mentioned in the present invention; and collecting the monoclonal antibody or the antigen-binding fragment thereof. After the collected antibody is purified, a substantially pure antibody can be obtained. Substantially pure means that the purity of the produced antibody can reach more than 90%, more than 91%, more than 92%, more than 93%, more than 94%, more than 95%, more than 96%, more than 97%, more than 98%, more than 99%, more than 99.5%, etc.

[0064] Pharmaceutical composition

[0065] The present invention also provides a pharmaceutical composition, comprising the monoclonal antibody or the antigen-binding fragment thereof; and a pharmaceutically acceptable carrier.

[0066] The pharmaceutically acceptable carrier mentioned is acceptable to the subject at the dosage or concentration used. Pharmaceutically acceptable carriers include, but are not limited to: buffers or salts, such as Tris, phosphates, citrates, sodium acetate, citric acid, sodium citrate and other organic acids; antioxidants, such as ascorbic acid; preservatives such as benzalkonium chloride; amino acids, such as histidine, histidine hydrochloride, glycine, glutamine, asparagine, arginine or lysine. The pharmaceutical preparations used in the subject are generally sterile, and sterile pharmaceutical preparations can be obtained by methods commonly used in the art, for example, by filtering with a sterile filter membrane. Those skilled in the art can select suitable pharmaceutically acceptable carriers according to the dosage form prepared by the pharmaceutical composition to prepare different dosage forms, for example, they can be prepared into various dosage forms such as injections, lyophilized agents, tablets, etc.

[0067] Reagent test kit

[0068] The present invention also provides a kit, which includes the monoclonal antibody or its antigen-binding fragment described above. The kit may also include a container, a buffer reagent, and a control such as a positive control and a negative control as required. Those skilled in the art may make corresponding selections as required. Accordingly, the kit may also include instructions for use to facilitate operation and use by those skilled in the art. Of course, it may also be made into a test strip for specific detection of the OmpA antigen targeting Mycobacterium tuberculosis.

[0069] The provided monoclonal antibody or antigen-binding fragment thereof can be used for the development of preventive vaccines or therapeutic drugs, thereby being used to treat or prevent tuberculosis or drug-resistant tuberculosis, and has strong targeting.

[0070] The present invention further provides a method for preventing or treating a disease, comprising: administering to a subject a preventive effective amount or a therapeutic effective amount of the above monoclonal antibody or its antigen-binding fragment, wherein the disease is tuberculosis. The provided monoclonal antibody or its antigen-binding fragment can be used to treat or prevent tuberculosis or drug-resistant tuberculosis.

[0071] The provided monoclonal antibody or antigen-binding fragment thereof can be used to prepare a drug or a kit. The drug can be used to prevent tuberculosis. The monoclonal antibody or antigen-binding fragment thereof can be used to prepare a kit and used as a reagent component in the kit for diagnosis of specific antigens.

[0072] The technical scheme of the present invention is described below by means of specific examples. It should be noted that these examples are only used to facilitate the understanding of those skilled in the art and should not be regarded as limiting the scope of protection of the present invention. Unless otherwise specified, the reagents used in the examples can be obtained commercially. Figure 1 As shown, the OmpA protein was first expressed using a prokaryotic expression system, and the expressed OmpA protein was mixed with an equal volume of aluminum adjuvant and injected subcutaneously, with an interval of two weeks, for three immunizations. Mouse spleen cells with high serum titers were selected and fused with SP2 / 0, and cells secreting specific antibodies were screened using HAT / HT medium. The sequence of the corresponding specific antibody was obtained by sequencing. At the same time, a variety of means were used to identify the function, subtype and related structure of the specific antibody, including but not limited to: using an antibody subtype identification kit to identify the antibody subtype; whole-bacterial ELISA to identify the recognition of Mycobacterium tuberculosis by antibodies; verification of Mycobacterium tuberculosis growth inhibition based on a mouse PBMC model; immune protection experiments after passive injection of antibodies infected with bovine Mycobacterium tuberculosis; bioinformatics prediction of antigen-antibody binding sites, etc.

[0073] Example 1

[0074] Example 1 An antibody targeting the surface protein OmpA of Mycobacterium tuberculosis is obtained by the following method, comprising:

[0075] 1. Prepare antibodies induced by the surface protein OmpA of Mycobacterium tuberculosis and screen them. The specific steps include:

[0076] First, an upstream primer (OmpA-F) and a downstream primer (OmpA-R) were designed to amplify the OmpA gene fragment. The primers used are shown below. The amplified OmpA gene fragment is shown in SEQ ID NO: 12 (the agarose gel electrophoresis result is shown in Figure 2 The sequence is shown in A in the figure, which encodes the protein sequence shown in SEQ ID NO: 11. The plasmid pET28a(+) was digested with EcoRI and HindIII and then homologous recombination was used to construct the vector. After sequencing, it was transformed into BL21 competent cells. IPTG was then used to induce protein expression, and Ni was used to 2+ The protein was purified by column affinity chromatography and identified by SDS-PAGE and Western-blot.

[0077] OmpA-F: 5'-CCGGAATTCGAGCGGCCCCAGTCCGTTAC-3' (SEQ ID NO: 13);

[0078] OmpA-R: 5'-CCCAAGCTTGTTGACCACGATCTCGACGCGAC-3' (SEQ ID NO: 14)

[0079] The SDS-PAGE results are as follows Figure 2 As shown in B, the label M represents the protein marker, the label 1 represents the protein induced by IPTG, and the label 2 represents the protein induced by Ni. 2+ Protein after column affinity purification. The results showed that after IPTG induction, the protein showed obvious expression. 2+ After column affinity purification, all impurity proteins were removed and the target protein was prepared.

[0080] The results of Western-blot are as follows Figure 2 As shown in middle C. The results show that the Mycobacterium tuberculosis surface protein OmpA was successfully obtained.

[0081] 2. Take 100 μg (1 mg / ml) of the OmpA protein prepared in step 1 and mix it with aluminum adjuvant (v / v=3:1), and immunize the mice subcutaneously in the back of the neck, once every two weeks, for a total of 3 times. Collect blood from the eye sockets of the mice, let it stand at room temperature for 1 hour, and then centrifuge to obtain serum, and use ELISA to identify the titer of mouse serum.

[0082] The results are as follows Figure 2 As shown in D, Balb / C-1, Balb / C-2, and Balb / C-3 in C represent three immunized mice, and NC represents the blank control, that is, compared with the three immunized mice, no immunization was performed. The serum titer of the mice was determined by ELISA to be 1.0935×10 6 above.

[0083] 3. Select the mouse with the highest titer, inject 100 μg (1 mg / ml) OmpA protein intraperitoneally, and take the spleen 3 days later. Use PEG1450 to fuse SP2 / 0 and spleen cells. HAT / HT medium is used to screen the specific antibody cell line of OmpA antigen. The corresponding cell line and antibody are both represented by 1E1 (the antibody 1E1 expressed is purified, and the identification results are as follows Figure 2 As shown in E, the heavy and light chains are shown in the figure).

[0084] The subtype of antibody 1E1 was identified as IgG2b using a mouse antibody subtype kit (manufacturer: Frdbio). Figure 2 (shown in F).

[0085] In addition, the recognition of antibody 1E1 against whole Mycobacterium bovis (M. bovis) and Bacillus Calmette-Guérin (BCG) was investigated. Bacterial ELISA was used to identify M. bovis and BCG cultured in 7H9 medium. The cultured bacteria were first heated at 80°C for 20 min to inactivate them, and then 1×10 7 CFU / well The bacteria were spread in a 96-well ELISA plate and dried at 60°C. Then the antibody 1E1 (500μg / ml) was diluted in multiples and added to the 96-well plate at 100μl / well, reacted with the bacteria at 37°C for 1h, and then 100μl of horseradish peroxidase (HRP)-labeled secondary antibody (1:10000) was incubated at 37°C for 1h. After TMB color development, the OD450 nm absorbance value was measured. The results are shown in Figure 2 As shown in G.

[0086] Example 2

[0087] Example 2 further identified the function of antibody 1E1.

[0088] After incubation with different concentrations of antibodies and BCG, macrophages J774a.1 were infected (MOI = 10). Flow cytometry was used to analyze the phagocytosis of BCG by mouse macrophages J774a.1. The results showed that antibody 1E1 promoted the phagocytosis of BCG (Mycoabcterium bovis BCG Pasteur) by macrophages in a concentration-dependent manner (the results are shown in Figure 3 MGO53 monoclonal antibody does not recognize Mycobacterium tuberculosis and was used as a negative control in this study.

[0089] To determine whether the antibody mediates the formation of phagolysosomes, the antibody was incubated with BCG and then infected with macrophages J774a.1. Fluorescence confocal microscopy analysis showed that antibody 1E1 could significantly promote the formation of phagolysosomes (the results are shown in Figure 3 C and D).

[0090] BCG was cultured in mouse whole blood mixed with different concentrations of antibody 1E1 at 37°C for 96 h. The surviving BCG in the system was counted by plating the culture on 7H10 plates. Significant BCG growth inhibition by antibody 1E1 was observed (the results are shown in Figure 3 (shown in E).

[0091] After intraperitoneal injection of 500 μg of antibody 1E1, mice were infected with 200 CFU of M. bovis. Two weeks later, the mice were killed and the lungs were ground and plated to count the number of bacteria in the lungs. Figure 3 As shown in F, the results indicate that antibody 1E1 can reduce M. bovis colonization in the lungs.

[0092] Example 3

[0093] Example 3 Antibody 1E1 was sequenced, and the sequencing results showed that the protein sequence encoded by the heavy chain variable region was as shown in SEQ ID NO:7, and the protein sequence encoded by the light chain variable region was as shown in SEQ ID NO:8.

[0094] The results of homology modeling of antibody 1E1 using Discovery Studio (DS) are as follows: Figure 4 As shown, it can be seen from the results that the complementarity determining region 3 (CDR3) of the H and L chains were annotated after homology modeling to predict the amino acid residues on the antigen-antibody contact surface.

[0095] Alphafold 3 predicted the structure of OmpA antigen, and the results are as follows Figure 5 As shown, from the results it can be seen that the OmpA protein presents a protein structure with a long tail, which is anchored at the N-terminus of the bacterial outer membrane, while most of the C-terminal structure is exposed on the bacterial surface, which will be beneficial to antibody recognition.

[0096] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "specific implementation", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0097] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. A protective monoclonal antibody or an antigen-binding fragment thereof targeting Mycobacterium tuberculosis OmpA, characterized in that: including a heavy chain variable region and a light chain variable region; The HCDR1-3 sequences of the heavy chain variable region are shown in SEQ ID NOs: 1, 2 and 3, respectively, or are sequences having an amino acid substitution, deletion or addition with respect to the sequences shown in SEQ ID NOs: 1, 2 or 3; The LCDR1-3 sequences of the light chain variable region are shown in SEQ ID NOs: 4, 5 and 6, respectively, or are sequences having an amino acid substitution, deletion or addition with respect to the sequence shown in SEQ ID NOs: 4, 5 or 6; The sequences shown in the HCDR1-3 and the sequences shown in the LCDR1-3 are obtained based on the IMGT definition scheme.

2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that: have: (a) the heavy chain variable region of SEQ ID NO:7, or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology to the heavy chain variable region of SEQ ID NO:7; and (b) a light chain variable region as set forth in SEQ ID NO:8, or a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence homology to the light chain variable region sequence as set forth in SEQ ID NO:8; Optionally, it has a heavy chain variable region shown in SEQ ID NO:7 and a light chain variable region shown in SEQ ID NO:

8.

3. An isolated polynucleotide, characterized in that The isolated polynucleotide encodes the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 2; Optionally, the polynucleotide comprises a sequence encoding a heavy chain variable region as shown in SEQ ID NO:9 and a sequence encoding a light chain variable region as shown in SEQ ID NO:

10.

4. A construct, characterized in that Contains the isolated polynucleotide according to claim 3.

5. A host cell, characterized in that Containing the isolated polynucleotide of claim 3 or the construct of claim 4.

6. A method for producing a monoclonal antibody or an antigen-binding fragment thereof, characterized in that: include: Cultivating a host cell, wherein the host cell is the host cell according to claim 5, and The monoclonal antibody or antigen-binding fragment thereof is collected from the culture.

7. A pharmaceutical composition, characterized in that include: The monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 2; as well as A pharmaceutically acceptable carrier.

8. A kit, characterized in that: include: The monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 2.

9. Use of the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 2 in the preparation of a reagent for detecting Mycobacterium tuberculosis OmpA, or in the preparation of a drug for preventing or treating a disease; Optionally, the disease is tuberculosis caused by Mycobacterium tuberculosis; Optionally, the drug is a preventive vaccine or a therapeutic drug.

10. An antigen protein or polypeptide, characterized in that: The antigen protein or polypeptide has the sequence shown in SEQ ID NO: 11; Optionally, the antigenic protein or polypeptide is encoded by the nucleic acid sequence shown in SEQ ID NO:12.

Citation Information

Patent Citations

  • Method for detecting high-sensitivity mycobacterium tuberculosis

    CN101923091A

  • Vaccine containing codon-optimized mycobacterium tuberculosis fusion protein AH

    CN112852848A

  • Mycobacterium tuberculosis c-di-AMP (adenosine monophosphate) clastic enzyme monoclonal antibody as well as preparation method and application thereof

    CN117186233A

  • Monoclonal antibody derived peptide inhibitors for mycobacterial DNA gyrase

    WO2004026910A1